ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatm…
Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership
All directors and officers of ALX Oncology Holdings Inc. are sourced directly from the SEC or manually.
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Each datapoint refers the most recent appearance of the corresponding person.
Officers & BofD Beta
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).
Total Compensation
Shows the total compensation per mentioned executive and board director.Each datapoint refers the most recent appearance of the corresponding person.
- No data, only available if we have DEF 14A compensations in place -
Officers
| Name & Position | Research | Last Appearance | |||
|---|---|---|---|---|---|
| - No data available - | |||||
Board of Directors (BofD)
| Name & Position | Research | Last Appearance | |||
|---|---|---|---|---|---|
| - No data available - | |||||